



#6  
9-6-03  
AP.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/016,283

Group: Not yet known

Filing Date: November 30, 2001

Examiner: R. Landsman

Title: Novel Tyrosine Kinase Receptors and Ligands

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Bernadette B. Fahey*  
Bernadette B. Fahey

June 20, 2003  
Date

RECEIVED

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97

JUN 27 2003

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Dear Sir:

In compliance with the Applicants' duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

[x] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

[ ] (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

- [ ] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or
- [ ] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

- [ ] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- [ ] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

- [ ] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

- [ ] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

- [ ] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

#### **REQUEST FOR TRANSFER OF REFERENCE COPIES**

- Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 08/644,271, filed May 10, 1996, be transferred to the subject application for consideration by the Examiner

**Fees**

The fee required for the filing of this Information Disclosure Statement is estimated to be \$ \_\_\_\_\_. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted

*Linda O. Palladino*

Linda O. Palladino  
Reg. No. 45,636  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400



FORM PTO-1449

Docket No.: REG 195BZ

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN: 10/016,283 Applicant: Valenzuela, et al.

Date Filed: November 30, 2001 Title: Novel Tyrosine Kinase Receptors and Ligands

Examiner: R. Landsman Art Unit: Not yet known

RECEIVED

June 20, 2003

JUN 27 2003

U.S. PATENT DOCUMENTS TECH CENTER 1600/2900

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Publication Number</u>	<u>Publication Date</u>	<u>Name</u>
--------------------------	----------------------	-------------------	---------------------------	-------------------------	-------------

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Date</u>	<u>Class Subclass</u>	<u>Translation Yes</u>	<u>No</u>
--------------------------	------------------------	-------------	----------------	-------------	-----------------------	------------------------	-----------

OTHER DOCUMENTS  
(Including Author, Title, Date, Pertinent Pages, etc.)Examiner Initial

THE JOURNAL OF NEUROSCIENCE, Vol. 12, No. 9, September 1992, pp. 3535-3544, RUPP, F., Et Al.: "Structure and Chromosomal Localization of the Mammalian Agrin Gene."

EMBL DATABASE, April 22, 1995, HEIDELBERG, HILLIER, L., Et Al.: "The WashU-Merck EST project, AC R12830."

EMBL DATABASE, October 7, 1995, HEIDELBERG, JAY, P.: "Human cDNAs from HE6W library, AC H58758."

NEURON, Vol. 8, No. 6, June 1992, pp. 1079-1086, FERNS, M., Et Al.: "RNA Splicing Regulates Agrin-Mediated Acetylcholine Receptor Clustering Activity on Cultured Myotubes."

NEURON, Vol. 15, No. 3, September 1995, pp. 573-584, VALENZUELA, D., Et Al., "Receptor Tyrosine Kinase Specific for the Skeletal Muscle Lineage: Expression in Embryonic Muscle, at the Neuromuscular Junction, and after Injury."

NEURON, Vol. 16, April 1996, pp. 755-767, GESEMANN, Et Al.: "Alternative Splicing of Agrin Alters Its Binding to Heparin, Dystroglycan, and the Putative Agrin Receptor."

- THE EMBO JOURNAL, Vol. 13, No. 12, 1994, pp. 2814-2821, HOCH, W., Et Al.: "Structural domains of agrin required for clustering of nicotinic acetylcholine receptors."
- THE EMBO JOURNAL, Vol. 15., No. 11, pp. 2625-2631, MEIER, T., Et Al.: "AChR phosphorylation and aggregation induced by an agrin fragment that lacks the binding domain for  $\alpha$ -dystroglycan."
- THE JOURNAL OF CELL BIOLOGY, Vol. 128, No. 4, February 1995, pp. 625-636, GESEMANN, M., "Acetylcholine Receptor-aggregating Activity Of Agrin Isoforms and Mapping of the Active Site."
- THE JOURNAL OF CELL BIOLOGY, Vol. 128, No. 6, March 1995, pp. 1121-1129, WALLACE, B.: "Regulation of the interaction of nicotinic acetylcholine receptors with the cytoskeleton by agrin-activated protein tyrosine kinase."
- ANNUAL REVIEWS IN NEUROSCIENCE, Vol. 18, 1995, pp. 443-462, BOWE, M. and FALLON, J.: "The Role Of Agrin In Synapse Formation."
- CELL, Vol. 85, No. 4, May 17, 1996, pp. 513-523, GLASS, D., Et Al.: "Agrin Acts via a MuSK Receptor Complex."

EXAMINER  
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Linda O. Palladino

Linda O. Palladino  
Reg. No. 45,636  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400